Neuroplasticity as a Target for the Pharmacotherapy of Psychiatric Disorders: New Opportunities for Synergy with Psychotherapy

Biological Psychiatry

Volumn 62, Issue 8, 2007, Pages 833-834

  Krystal, John H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSERINE; GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANXIETY DISORDER; ARTICLE; DRUG EFFECT; DRUG MECHANISM; HUMAN; MENTAL DISEASE; NERVE CELL PLASTICITY; NEUROMODULATION; PRIORITY JOURNAL; PSYCHOTHERAPY; STIMULUS RESPONSE;

EID: 34848881031     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2007.08.017     Document Type: Note

References (24)

1. Krystal J.H. Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly 137 (2007) 215-216
2. Ressler K.J., Rothbaum B.O., Tannenbaum L., Anderson P., Graap K., Zimand E., et al. Cognitive enhancers as adjuncts to psychotherapy: Use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61 (2004) 1136-1144
3. Hofmann S.G., Meuret A.E., Smits J.A., Simon N.M., Pollack M.H., Eisenmenger K., et al. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63 (2006) 298-304
4. Davis M. Role of NMDA receptors and MAP kinase in the amygdala in extinction of fear: Clinical implications for exposure therapy. Eur J Neurosci 16 (2002) 395-398
5. Davis M., Ressler K., Rothbaum B.O., and Richardson R. Effects of D-cycloserine on extinction: Translation from preclinical to clinical work. Biol Psychiatry 60 (2006) 369-375
6. Krystal J.H., D'Souza D.C., Mathalon D., Perry E., Belger A., and Hoffman R.E. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology 169 (2003) 215-233 (Berl)
7. Emmett M.R., Mick S.J., Cler J.A., Rao T.S., Iyengar S., and Wood P.L. Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30 (1991) 1167-1171
8. Watson G.B., Bolanowski M.A., Baganoff M.P., Deppeler C.L., and Lanthorn T.H. D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510 (1990) 158-160
9. Hood W.F., Compton R.P., and Monahan J.B. D-cycloserine: A ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98 (1989) 91-95
10. Krueger J.M., O'Connor A.J., and Kelso S.R. Glycine site agonists exhibit subunit specific effects on NMDA receptors expressed in Xenopus oocytes. Abstr Soc Neurosci 23 (1997) 945
11. Danysz W., and Parsons C.G. Glycine and N-methyl-D-aspartate receptors: Physiological significance and possible therapeutic applications. Pharmacol Rev 50 (1988) 597-664
12. Sheinin A., Shavit S., and Benveniste M. Subunit specificity and mechanism of action of NMDA partial agonist D-cycloserine. Neuropharmacology 41 (2001) 151-158
13. Pittenger C., Sanacora G., and Krystal J.H. The NMDA receptor as a therapeutic target for major depressive disorder. CNS Neurol Disord Drug Targets 6 (2007) 101-115
14. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R., Charney D.S., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies for neuropsychiatric disorders. Harv Rev Psychiatry 7 (1999) 125-133
15. Heresco-Levy U., Javitt D.C., Gelfin Y., Gorelik E., Bar M., Blanaru M., and Kremer I. Controlled trial of D-cycloserine adjuvant therapy for treatment-resistant major depressive disorder. J Affect Disord 93 (2006) 239-243
16. Heresco-Levy U., Kremer I., Javitt D.C., Goichman R., Reshef A., Blanaru M., and Cohen T. Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5 (2002) 301-307
17. Torras-Garcia M., Lelong J., Tronel S., and Sara S.J. Reconsolidation after remembering an odor-reward association requires NMDA receptors. Learn Mem 12 (2005) 18-22
18. Lee J.L., Milton A.L., and Everitt B.J. Reconsolidation and extinction of conditioned fear: Inhibition and potentiation. J Neurosci 26 (2006) 10051-10056
19. Duman R.S. Role of neurotrophic factors in the etiology and treatment of mood disorders. Neuromolecular Med 5 (2004) 11-25
20. Kalivas P.W. Neurobiology of cocaine addiction: Implications for new pharmacotherapy. Am J Addict 16 (2007) 71-78
21. Nestler E.J., Barrot M., and Self D.W. DeltaFosB: A sustained molecular switch for addiction. Proc Natl Acad Sci U S A 98 (2001) 11042-11046
22. Kumar A., Choi K.H., Renthal W., Tsankova N.M., Theobald D.E., Trong H.T., et al. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 48 (2005) 303-314
23. Castner S.A., Williams G.V., and Goldman-Rakic P.S. Reversal of antipsychotic-induced working memory deficits by short-term dopamine D1 receptor stimulation. Science 287 (2000) 2020-2022
24. Castner S.A., and Williams G.V. Tuning the engine of cognition: A focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63 (2007) 94-122